Drugs / rilparencel
rilparencel
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05018416 | Jul 2021 → May 2025 | chronic kidney disease, type 1 diabetes mellitus, type 2 diabetes mellitus | Prokidney | Completed | Mixed |
| Phase 31 trial | ||||||
| Phase 3 | NCT05099770 | Jan 2022 → Dec 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Prokidney | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-07-08 | Prokidney | Results ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes prokidney.com ↗
In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel injections (one in each kidney). |
| 2024-11-12 | Prokidney | Regulatory ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting prokidney.com ↗
FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel |
| 2024-06-10 | Prokidney | Results ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates prokidney.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rilparencel | “assessed rilparencel (an autologous cell therapy composed of cells obtained by kidney biopsy)” PMID 41481370 ↗ Jan 2026 |
| Known as | Neo kidney augment (nka) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314704 ↗ |
| Known as | REACT | “Renal Autologous Cell Therapy (REACT/ rilparencel)” NCT05099770 ↗ |
| Modality | Cell therapy | “rilparencel (an autologous cell therapy composed of cells obtained by kidney biopsy)” PMID 41481370 ↗ Jan 2026 |
| Route | Other | “Cohort 1 received two rilparencel injections percutaneously into the kidney cortex” PMID 41481370 ↗ Jan 2026 |